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Summary
CD40 is expressed on a variety ofcells, including B cells, monocytes, dendritic cells, and fibro-
blasts. CD40 interacts with CD40L, a 30-33-kD activation-induced CD4+ T cell surface mol-
ecule. CD40L-CD40 interactions are known to play key roles in B cell activation and differen-
tiation in vitro and in vivo. We now report that normal human endothelial cells also express
CD40 in situ, and CD40L-CD40 interactions induce endothelial cell activation in vitro. Fro-
zen sections from normal spleen, thyroid, skin, muscle, kidney, lung, or umbilical cord were
studied for CD40 expression by immunohistochemistry. Endothelial cells from all tissues stud-
ied express CD40 in situ. Moreover, human umbilical vein endothelial cells (HUVEC) express
CD40 in vitro, and recombinant interferon y induces HUVEC CD40 upregulation. CD40 ex-
pression on HUVEC is functionally significant because CD40L+ Jurkat T cells or CD40L+ 293
kidney cell transfectants, but not control cells, upregulate HUVEC CD54 (intercellular adhesion
molecule-1), CD62E (E-selectin), and CD106 (vascular cell adhesion molecule-1) expression
in vitro. Moreover, the kinetics of CD40L-, interleukin 1-, or tumor necrosis factor ot-induced
CD54, CD62E, and CD106 upregulation on HUVEC are similar. Finally, CD40L-CD40 in-
teractions do not induce CD80, CD86, or major histocompatibility complex class 11 expression
on HUVEC in vitro. These results demonstrate that CD40L-CD40 interactions induce endo-
thelial cell activation in vitro. Moreover, they suggest a mechanism by which activated CD4+
T cells may augment inflammatory responses in vivo by upregulating the expression of endo-
thelial cell surface adhesion molecules.
ndothelial cells express surface molecules, such as CD54
(intercellular adhesion molecule-1), CD62E (E-selec-
tin), and CD106 (vascular cell adhesion molecule-1), that
mediate adhesive interactions with leukocytes (1, 2) . The
expression of endothelial cell surface adhesion molecules
orchestrates recruitment of leukocytes to sites of inflamma-
tion and therefore is subject to tight regulation (1, 2) . Rest-
ing endothelial cells express low levels of CD54 and mini-
mal or no CD62E or CD106. After activation with IL-1,
TNF-ot, or LPS, endothelial cells rapidly upregulate CD54,
CD62E, and CD106 expression (1, 2). CD4+ T cells may
contribute to upregulatation of endothelial cell surface ad-
hesion molecules by inducing endothelial cells or other tar-
get cells to secrete IL-1 or TNF-et (3). The molecular de-
tails involved in CD4+ T cell-endothelial cell interactions
that induce endothelial cell activation, however, have not
been completely delineated.
Interestingly, an immunohistologic study demonstrated
that endothelial cells within rheumatoid arthritis synovial
membrane express CD40 (4), a molecule whose counter-
receptor is expressed on CD4+ T cells. CD40 is a 50-kD
cell surface molecule also expressed on B cells (5, 6), mono-
cytes (7), dendritic cells (8), basophils (9), epithelial cells (10,
11), and fibroblasts (12) . CD40 interacts with CD40L (T
cell-13 cell-activating molecule, gp39, TNF-related activa-
tion protein), a 30-33-kD cell surface molecule transiently
expressed on activated CD4+ T cells (13-18). CD40L-CD40
interactions have been most extensively studied in the con-
text ofT-B cell interactions (19, 20), and they are essential
for T cell-dependent B cell differentiation in vitro and in
vivo. Although the functional significance ofligating CD40
on non-13 cells in vivo is currently unknown, CD40 signal-
ing induces activation, differentiation, or proliferation of
monocytes (7), dendritic cells (21), epithelial cells (11), or
fibroblasts (12) in vitro.
In this regard, CD40 ligation induces the secretion of
various cytokines from monocytes (7), dendritic cells (21),
epithelial cells (11), and fibroblasts (12) . CD40L-CD40 in-
teractions also upregulate CD54 and CD106 expression on
fibroblasts (12), and they upregulate CD80, CD86, and
MHC class 11 expression on dendritic cells (21) . Moreover,
CD40L-mediated signals induce morphologic changes in
cultured dendritic cells (21), proliferation of fibroblasts (12),
and tumoricidal activity by monocytes (7) .
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mal tissue express CD40. Moreover, we show that human
umbilical vein endothelial cells (HUVEC)' express CD40
in vitro and that CD40L-CD40 interactions induce the up-
regulation of endothelial cell surface adhesion molecules.
Materials and Methods
mAbs, Lectins, and Cell Lines.
￿
The IgG2a murine anti-CD40L
mAb (5C8) was previously generated in our laboratory (13). Hy-
bridomas W6/32 (anti-MHC class I), L243 (anti-MHC class II),
3C10 (anti-CD14), THB.5 (anti-CD21), G28.5 (anti-CD40),
and GAP 8.3 (anti-CD45) were purchased from American Type
Culture Collection (Rockville, MD). FITC conjugated anti-CD13,
FITC conjugated anti-CD19, and PE conjugated anti-CD54 mAbs
were purchased from Biosource International (Camarillo, CA),
and anti-CD34 mAb was obtained from Biogenex (San Ramon,
CA). An additional anti-CD54 mAb as well as anti-CD62E and
anti-CD106 mAbs were kindly provided by Biogen, Inc. (Cam-
bridge, MA). L243 and mAbs provided by Biogen, Inc., were bi-
otinylated as previously described (22). PE-conjugated anti-CD80
and biotinylated anti-CD86 mAbs were purchased from Becton
Dickinson & Co. (Mountain View, CA) and PharMingen (San
Diego, CA), respectively. Isotype control mAbs used for FACS©
analysis were purchased from Becton Dickinson & Co. or CAL-
TAG Laboratories (South San Francisco, CA). P1.17 is an irrele-
vant control IgG2a murine mAb (Biogen, Inc.) used for func-
tional studies. FITC-conjugated Ulex europaeus agglutinin-1
(UEA-1) was obtained from Sigma Chemical Co . (St. Louis,
MO), and streptavidin-PE was purchased from Calbiochem (La
Jolla, CA).
D1 .1 is a Jurkat T cell subclone that constitutively expresses
CD40L (13) . B2.7 is a CD40L- Jurkat T cell subclone (13) . Sta-
ble transfected CD40L+ 293 kidney cells or CD8+ 293 kidney
cells were generated as previously reported (22). Ramos 2G6 B
cells respond to CD40L-mediated signals (23) and were obtained
from American Type Culture Collection.
Endothelial Cell Cultures. HUVEC were cultured in M199
media (Gibco Laboratories, Grand Island, NY) supplemented
with 25% FCS (SummitBiotechnology, Ft. Collins, CO), 5% hu-
man serum (Gemini, Calabasas, CA), 90 jig/ml heparin (Sigma
Chemical Co.), 15 l.tg/ml endothelial cell growth factor (Collab-
orative Research Inc., Bedford, MA), and 1% penicillin-strepto-
mycin (Sigma Chemical Co.) (M199 complete media). HUVEC
were passaged by treatment for 3 min with 1% trypsin-EDTA
(Sigma Chemical Co .) . All HUVEC experiments were performed
in M199 complete media after one to three passages.
Studies on the Effects of Cytokines on HUVEC CD40 Expression.
HUVEC in six-well plates (Nunc, Roskilde, Denmark) were
grown to near confluence and then incubated with 1,000 U/ml
rIFN-y (Biogen), 10 pg/ml rIL-la (R&D Systems, Inc., Minne-
apolis, MN), or 200 U/ml rTNF-a (Upstate Biotechnology, Inc.,
Lake Placid, NY)in 3 ml ofM199 complete medium. At the indi-
cated times, medium was aspirated, cells were washed once with
saline, and 1 ml of 1% trypsin-EDTA was added to the wells. Cold
Isocove'smodified Dulbecco's medium (Gibco Laboratories) con-
taining 10% FCS (SummitBiotechnology) was addedto the wells
after 3 min, and the cells were collected for FACS° analysis.
(Abbreviations used in this paper: HUVEC, humanumbilicalvein endothe-
lial cells; MR, mean fluorescence intensity; UEA, Ulex europaeus agglu-
tinin-' .
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Studies on Functional Consequences of HUVEC CD40 Ligation.
HUVEC in six-well plates were cultured with 106 CD40L+ Jur-
kat D1 .1 cells, CD40L- Jurkat B2 .7 cells, CD40L+ 293 kidney
cell transfectants or CD8+ kidney cell transfectants. Where indi-
cated, CD40L' cellswere pretreated with anti-CD40L mAb 5C8
(10 Wg/ml) or isotype control mAb P1 .17 (10 wg/ml) before ad-
dition to HUVEC. After the indicated time in culture, the cells
were,collected by trypsinization, and two-color FACS° analyses
were performed.
Functional Studies ofCD40 Ligation on Ramos 2G6 Cells.
￿
Con-
trol experiments of CD40 ligation on Ramos 2G6 cells were per-
formed by culturing 2 X 105 Ramos 2G6 cells with 105 D1 .1
cells or control cells for 24 h in 96-well plates containing 200 p,l
of Isocove's Modified Dulbecco's Medium (Gibco Laboratories)
supplemented with 10% FCS (Summit Biotechnology) and 1%
penicillin-streptomycin (Sigma Chemical Co.) .
Cytofuorographic Analysis.
￿
Single-or two-colorcytofluorographic
analyses were performed as previously described (13, 22). HUVEC
were distinguished fromJurkat T cells in two-color FACS® analyses
by positive staining with anti-CD13 mAb. CD13 (N-aminopepti-
dase) is expressed on monocytes, fibroblasts, and endothelial cells
but is not expressed on T cells (24). Additionally, UEA-1, a lectin
that selectively binds endothelial cells (25), was used to discrimi-
nate HUVEC from Jurkat cells or 293 kidney cells. Fluorescence
intensity was measured on a FACScan® cytofluorograph with
Consort-30 software (Becton Dickinson & Co.). Mean fluores-
cence intensity (MFI) refers to values normalized to the log scale
as calculated by Consort-30 software.
Characterization of Endothelial Cell CD40 Expression In Situ.
Frozen sections of normal spleen, thyroid, skin, muscle, kidney,
lung, or umbilical cord were studied for CD40 expression, as pre-
viously described (23) . Immunohistologic analysis was performed
with the indicated mAbs or control mouse IgG (Sigma Chemical
Co.), and reactivity was detected using a Vector ABC Elite kit
and 3-amino-9-ethylcarbazole (Vector Laboratories, Inc., Burlin-
game, CA) according to the manufacturer's instructions .
Results
In Situ and In Vitro Characterization ofEndothelial Cell CD40
Expression. The first series of experiments was performed
to determine if normal endothelial cells express CD40 in situ.
Therefore, frozen sections obtained from normal spleen,
thyroid, skin, muscle, kidney, lung, or umbilical cord were
stained with anti-CD40 mAb or control mouse IgG, and
endothelial cell reactivity was noted. Additional controls
included staining with anti-CD34 mAb (reactive with he-
matopoietic stem cells and endothelial cells [26]) or anti-
CD21 mAb (reactive with B cells and epithelial cells [10]).
Endothelial cells from all tissues studied express CD40 in
situ. Fig. 1 demonstrates representative CD40 staining ofen-
dothelial cells in normal skin or muscle. The pattern of en-
dothelial reactivity was similar to that seen with anti-CD34
mAb (Fig. 1). In contrast, endothelial cells did not reactwith
anti-CD21 mAb (Fig. 1) or mouse IgG (not shown) .
To further explore endothelial cell CD40 expression and
function in vitro we next asked if cultured HUVEC also
express CD40 as determined by FACS© analysis. Morpho-
logic and phenotypic analyses demonstrated that the cultures
did not contain significant numbers of contaminating non-
endothelial cells (not shown). HUVEC constitutively expressFigure 1 .
￿
Expression of CD40 on endothelial cells in situ . Shown are immunohistologic studies of frozen sections demonstrating the expression of
CD40 (a and d), CD34 (b and e), and CD21 (c andf) in normal skin (a-c) or muscle (df) . X40 .
CD40 in vitro (Fig. 2) . Similar results were obtained from
HUVEC isolated from 15 individuals . Moreover, rIFN-y,
in contrast to rIL-1a or rTNF-ot, induces a two- to three-
fold increase in HUVEC CD40 expression (Table 1) . To-
gether, these studies demonstrate that endothelial cells from
normal tissue express CD40 in situ and in vitro and that
rIFN-y upregulates endothelial cell CD40 expression in
vitro .
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Effect of CD40L-CD40 Interactions on HUVEC CD54,
CD62E, and CD106 Expression . Activated endothelial cells
rapidly upregulate expression of cell surface molecules, such
as CD54, CD62E, andCD106, which play important roles in
mediating intercellular adhesive interactions (1, 2) . Interest-
ingly, ligation ofCD40 onB cells (27) or fibroblasts (12) in-
duces the upregulation ofadhesion molecules . Therefore, we
next asked ifCD40L-CD40 interactions affect the expressionFigure 2.
￿
Expression ofCD40 on HUVEC in vitro. Shown are over-
lapping FACS® analyses of CD 14, CD40, CD45, or isotype control ex-
pression on HUVEC after the first passage. The mean fluorescence inten-
sity of CD 14, CD40, CD45, or isotype control expression is 7, 24, 5, and
9, respectively. The data shown is representative ofCD40 expression on
HUVEC isolated from 15 umbilical cords.
of CD54, CD62E, or CD106 on HUVEC in vitro as deter-
mined by two-color FACS® analysis. HUVEC were cul-
tured with CD40L+ 293 kidney cell transfectants or CD8+
293 kidney cell transfectants. As a positive control, HUVEC
were also cultured with rIL-1a. CD40L+ 293 cells, but not
CD8+ 293 cells, induce CD54, CD62E, and CD106 upreg-
ulation on HUVEC (Fig. 3) . Additionally, CD40L+ Jurkat
D1 .1 cells, in contrast to CD40L- B2.7 cells, upregulate
CD54, CD62E, and CD106 on HUVEC (Figs. 3 and 4) in a
manner that is inhibited by anti-CD40L mAb 5C8, but not
by control mAb (not shown) . The kinetics of adhesion
molecule upregulation induced by CD40L-CD40 interac-
tions is similar to that reported for IL-1- and TNF-a-
induced upregulation (1, 2) (Fig. 4). Together, these studies
demonstrate that CD40L-CD40 interactions are sufficient
to upregulate HUVEC CD54, CD62E, and CD 106 expres-
sion in vitro.
Determining if CD40L-CD40 Interactions Upregulate CD80,
CD86, or MHC Class If Expression on HUVEC. Activated
endothelial cells are competent to express MHC class II
molecules and deliver costimulatory signals to T cells (3,
28). Ligation of CD40 on B cells or dendritic cells upregu-
Table 1.
￿
Effect of Cytokines on HUVEC CD40 Expression
HUVEC expression
Stimuli
￿
CD40 (MFI)
￿
CD54 (MFI)
Media
￿
17
￿
22
rIFN-y
￿
42
￿
44
HL-la
￿
24
￿
51
rTNF-ot
￿
22
￿
54
Shown is theMFI ofCD40 or CD54 expression on HUVEC cultured
in the presence or absence ofrIFN-y (1,000 U/ml), rIL-1a (10pg/ml),
or rTNF-a (200 U/ml) for48 h. CD40 or CD54 MFI was determined
by FACS° analysis, and background staining of control mAb is sub-
tracted for each value. Similar results were obtained in two additional
experiments with different HUVEC lines.
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UEA-1 Fluorescence
Figure 3.
￿
Effects of CD40L-CD40 interactions on HUVEC CD54,
CD62E, and CD106 expression. Shown are two-color contour graphs
demonstrating HUVEC CD54, CD62E, andCD106 expression after cul-
ture with medium, CD40L+ Jurkat D1 .1 cells, CD8` 293 kidney cell
transfectants, or CD40L+ 293 kidney cell transfectants for 6 h. The x axis
demonstrates UEA-1 expression and the y axis demonstrates CD54 (left),
CD106 (middle), or CD62E (right) expression. The number in the upper
right-hand comer ofeach graph indicates thepercentage of UEA-1' cells
expressing CD54, CD106, or CD62E, as indicated (background staining
ofcontrol mAbis subtracted for each value) . The data shown is represen-
tative ofthree similar experiments with different HUVEC lines.
lates MHC class II expression, as well as the expression of
the costimulatory molecules CD80 and CD86 (21, 22, 27,
29, 30). Therefore, the next series of experiments deter-
mined if CD40L-CD40 interactions similarly upregulate
MHC class II, CD80, or CD86 expression on HUVEC.
HUVEC were cultured with CD40L+ D1 .1 cells, CD40L-
B2.7 cells, or rIFN-y for 24 or 48 h, and CD54, CD80,
CD86, andMHC class II expression was determined by two-
color FACS© analysis. Preliminary experiments demon-
strated that trypsinization did not affect CD80, CD86, or
MHC class II expression on controlB cell lines (not shown).
As a positive control for CD40L-mediated CD80, CD86,
and MHC class II upregulation, D1 .1 cells were cultured
with Ramos 2G6 B cells (23). In contrast to the effects of
CD40 ligation on B cells or dendritic cells, CD40L-CD40
interactions do not upregulate MHC class II, CD80, or
CD86 expression on HUVEC (Table 2) .
CD40 is a cell surface molecule constitutively expressed
on a variety of cells, including B cells (5, 6), monocytes (7),
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dendritic cells (8), epithelial cells (10, 11), basophils (9), and
fibroblasts (12). The counterreceptor for CD40 is CD40L,
a 30-33-kD activation-induced, transiently expressed CD4+
T cell surface molecule (13-18) . In this article, we studied
the expression and function of CD40 on normal endothe-
lial cells . We show that endothelial cells in the spleen, thy-
roid gland, skin, muscle, kidney, lung, or umbilical cord ex-
press CD40 in situ. This finding is consistent with a
previous report that endothelial cells in rheumatoid arthritis
synovial membrane express CD40 (4). In addition, HUVEC
express CD40 in vitro. Most importantly, CD40 expression
on endothelial cells is functionally significant because
CD40L+ Jurkat T cells or CD40L+ 293 kidney cell transfec-
tants, but not control cells, upregulate the expression of in-
tercellular adhesion molecules CD54 (intercellular adhesion
molecule-1), CD62E (E-selectin) and CD106 (vascular cell
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30
Figure 4.
￿
Kinetic analysis of CD40L-induced HUVEC
CD54, CD62E, and CD106 upregulation. Shown are the
percentages of HUVEC expressing CD54, CD62E, or
CD106 after culture with CD40L+ Jurkat D1.1 cells (a) or
CD40L- Jurkat B2.7 cells (b) for 6 or 24 h. The percent-
ages of HUVEC expressing CD54, CD62E, or CD106
were determined by two-color FRCS® analysis (back-
ground staining of control mAb is subtracted for each
value) . The data shown is representative of three similar
experiments with different HUVEC lines.
adhesion molecule-1) on HUVEC. Together, these studies
demonstrate that endothelial cells express CD40, and
CD40L-CD40 interactions induce endothelial cell activa-
tion in vitro.
While this article was in review, two papers were pub-
lished demonstrating that dermal endothelial cells express
CD40 in situ and rsCD40L induces upregulation of HU-
VEC adhesion molecules in vitro (31, 32). Our work con-
firms and significantly extends these studies by demonstrat-
ing that (a) endothelial cells in a variety of tissues express
CD40; (b) the kinetics of CD40L-, IL-1-, and TNF-et-
mediated upregulation of CD54, CD62E, or CD106 ex-
pression on HUVEC are similar; (c) in contrast to effects on
B cells and dendritic cells, CD40L-CD40 interactions do
not upregulate CD80, CD86, or MHC class lI expression
on HUVEC; and most importantly, (d) cell surface CD40LTable 2.
￿
Effect ofCD40L-CD40 Interactions on HUVECMHC Class 77, CD80, and CD86 Expression
Shown is the mean fluorescence intensity ofHUVEC CD54, CD80, CD86, or MHC class II expression after culture with medium, rIFN-'Y (1,000
U/ml), CD40L+ Jurkat D1 .1 cells, or CD40L- B2.7 cells for 48 h. In a parallel experiment, the CD40L-responsive Ramos 2G6 B cell line (23) was
cultured with medium, CD40L+ Jurkat D1.1 cells, or CD40L- B2.7 cells for 24 h. HUVEC or Ramos 2G6 MHC class 11, CD54, CD80, and
CD86 expression was determined by two-color FRCS® analysis. Background staining of control mAb is subtracted for each value. Shown is repre-
sentative of three similar experiments with different HUVEC lines.
induces endothelial cell activation. This is not a trivial point
because CD40L physiologically exists as a cell surface mol-
ecule and delivers contact-dependent signals to CD40+ cells.
In this regard, CD40L is not known to normally function
as a secreted cytokine. Interestingly, in contrast to our studies
and those ofKarmann et al. (31), Hollenbaugh and colleagues
did not observe CD40L-mediated CD106 upregulation on
HUVEC (32). This may be caused by methodological dif-
ferences used to study upregulation ofHUVEC cell surface
molecules, or alternatively, by the rsCD40L molecule used
by this group.
Together, these studies suggest that CD40L+CD4+ T
cells play roles in augmenting the inflammatory process by
interacting with CD40+ endothelial cells and upregulating
CD54, CD62E, and CD106 expression. The functional
consequences of this interaction would enable further ad-
hesion and transmigration of immune cells at sites of in-
flammation. The fact that CD40 ligation regulates the ex-
pression of endothelial cell surface adhesion molecules is
consistent with a general role for CD40 signaling in regu-
lating the expression and/or function of adhesion mole-
cules on a variety of cells. In this regard, we have recently
shown that CD40L-mediated signals induce CD54 and
CD106 upregulation on fibroblasts cultured from synovial
membrane (12). CD40 ligation also upregulates CD54 ex-
pression on B cells (27) and induces CD54-dependent ho-
moaggregation of B cells (33) .
In contrast to effects on B cells and dendritic cells, CD40
ligation does not upregulate MHC class 11, C1380, or
CD86 expression on HUVEC in vitro. This finding is con-
sistent with previous studies suggesting that human endo-
We thank Valerie Henriques and the nursing staff at the Allen Pavilion maternity ward for providing umbil-
ical cords. We thank Dr. Seth Lederman for thoughtful discussions and suggestions regarding this work. This
article is dedicated to the memory ofJerald Brett.
This work was supported in part by National Institutes of Health grants K08-AR-01904 to M. J. Yellin,
HL21006, HL42833, and HL50629 to D. Stern, and R01-AI-14969 to L. Chess. M.J. Yellin is the recipient
1862
￿
CD40 Expression on Endothelial Cells
thelial cells do not express CD80 (28). CD80 and CD86
deliver important costimulatory signals to T cells necessary
for IL-2 production and proliferation. Interestingly, endo-
thelial cells are competent to present Ag to T cells in vitro,
and they deliver appropriate costimulatory signals to T cells
which are required for IL-2 production and proliferation
(28). The costimulatory molecules expressed on endothelial
cells are not precisely known. It will be ofinterest to deter-
mine if CD40L-mediated signals modulate the capacity of
endothelial cells to activate T cells.
Finally, endothelial cells are activated in a variety of dis-
eases mediated by CD4+ T cells. For example, endothelial
cell surface adhesion molecules are upregulated in rheuma-
toid arthritis (34) and scleroderma (35) . In addition, CD4+
T cells may play roles in atherosclerosis (36) and accelerated
atherosclerosis associated with transplantation (37). The
precise role of CD40L-mediated interactions with endo-
thelial cells in these diseases is not known. It is of interest,
however, that an antibody to CD40L, MR1, inhibits mu-
rine models of diseases mediated by CD4+ T cells and/or
inflammatory cell infiltrates. For example, MR1 prevents
the synovial lining cell hypertrophy and cellular infiltrate
associated with collagen-induced arthritis, a murine model
ofrheumatoid arthritis (38) . Moreover, MR1 inhibits a mu-
rine model of multiple sclerosis (experimental allergic en-
cephalomyelitis) and inhibits allograft rejection (39) . It is
possible that blocking CD40L-dependent interactions with
endothelial cells and/or fibroblasts mediates, in part, these
effects ofMR1 . Together, these studies suggest that CD40L-
CD40 interactions on the surface of endothelial cells may
play immunopathogenic roles in inflammatory diseases.
Conditions CD54
HUVEC
CD80
expression
CD86
(MFI)
MHC class II CD54
Ramos
CD80
expression (MFI)
CD86 MHC class II
Media 8 0 1 0 22 0 7 128
D1 .1 78 0 0 0 71 8 13 223
132.7 23 0 1 1 25 1 7 127
rIFN-y 16 0 0 97 ND ND ND NDReferences
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